insulin, Novo Nordisk and Minnesota
CBS News · 2d
Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.
Fox 9 · 2d
MN Novo Nordisk settlement over insulin pricing [RAW]
Minnesota Attorney General Keith Ellison announced a settlement with Novo Nordisk regarding the high price of insulin. The settlement requires Novo Nordisk to offer its insulin products to Minnesotans for no more than $35 a month over the next five years.
FiercePharma · 1d
Novo Nordisk expands Ozempic's turf with new FDA nod to curb kidney disease risks
When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical director suggested the results could help set a new standard for “holis | The FDA on Tuesday gave Ozempic a thumbs-up to reduce the risk of kidney disease worsening,
CNN · 1d
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,
U.S. News & World Report · 1d
US FDA Approves Novo Nordisk's Ozempic to Cut Risk of Diabetic Kidney Disease Progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Results that may be inaccessible to you are currently showing.
Hide inaccessible results